ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      USA Passive

      iShares U.S. Pharmaceuticals ETF

      The iShares U.S. Pharmaceuticals ETF (the ¡°Fund¡±) seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector.

      $71.32

      Compare similar ETFs

      Fund Size
      Dividend
      Fees
      Current
      U.S. Pharmaceuticals ETF IHE
      Fund Size
      $583M
      Dividend
      1.6%
      Fees
      0.39%
      Core S&P 500 ETF IVV
      Fund Size
      $626B
      Dividend
      1.2%
      Fees
      0.03%
      Core U.S. Aggregate Bond ETF AGG
      Fund Size
      $128B
      Dividend
      3.8%
      Fees
      0.03%
      S&P 500 Equal Weight ETF RSP
      Fund Size
      $73B
      Dividend
      1.5%
      Fees
      -
      Schwab U.S. Dividend Equity ETF SCHD
      Fund Size
      $68.2B
      Dividend
      3.7%
      Fees
      0.06%
      View 400 similar ETFs →

      Average metrics of all companies in portfolio

      Compare to
      Market
      Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $305B
      Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 1.59 %
      Beta Indicates the relationship between the price performance of a share and the market. 0.5063
      P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 31.47
      Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -57.94
      Profitable Companies 75
      PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 103.79
      Price to Sales Ratio Market cap divided by the revenue in the most recent year. 8.69
      Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 16.69
      Compare to
      Market
      Enterprise Value to EBIT Enterprise Value divided by EBIT 14.44
      Enterprise Value to Revenue Enterprise value divided by revenue 12.33
      Total Debt to Enterprise Value Total debt divided by enterprise value 0.09
      Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.7034
      Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -55.94%
      Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
      Return on Equity Equity divided by market cap. 24.29%
      Return on Assets Indicates a company's profitability in relation to its total assets. 6.76%
      Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 16.77%

      Industries

      Healthcare 74.4%
      N/A 25.6%

      Market cap

      Micro Cap 3%
      Small Cap 6%
      Mid Cap 17%
      Large Cap 21%
      Mega Cap 53%

      39 Investments

      P/E-Ratio
      Total Investment
      Weight
      JOHNSON & JOHNSON logo

      JNJ - Manufacturing

      JOHNSON & JOHNSON

      P/E-Ratio
      18.9
      Total Investment
      $125M
      Weight
      22.6%
      ELI LILLY AND COMPANY logo

      LLY - Manufacturing

      ELI LILLY AND COMPANY

      P/E-Ratio
      47.7
      Total Investment
      $122M
      Weight
      22.2%
      BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares logo

      BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares

      P/E-Ratio
      n/a
      Total Investment
      $32M
      Weight
      5.8%
      ROYALTY PHARMA PLC logo

      RPRX - Manufacturing

      ROYALTY PHARMA PLC

      P/E-Ratio
      14.9
      Total Investment
      $26.8M
      Weight
      4.9%
      VIATRIS INC. logo

      VIATRIS INC.

      P/E-Ratio
      n/a
      Total Investment
      $25.2M
      Weight
      4.6%
      PFIZER INC. logo

      PFIZER INC.

      P/E-Ratio
      n/a
      Total Investment
      $25.1M
      Weight
      4.6%
      MERCK & CO., INC. logo

      MERCK & CO., INC.

      P/E-Ratio
      n/a
      Total Investment
      $25M
      Weight
      4.5%
      ZOETIS INC. logo

      ZTS - Manufacturing

      ZOETIS INC.

      P/E-Ratio
      26.7
      Total Investment
      $23.8M
      Weight
      4.3%
      BRISTOL-MYERS SQUIBB CO logo

      BMY - Manufacturing

      BRISTOL-MYERS SQUIBB CO

      P/E-Ratio
      -16.7
      Total Investment
      $23.4M
      Weight
      4.2%
      ELANCO ANIMAL HEALTH INCORPORATED logo

      ELAN - Manufacturing

      ELANCO ANIMAL HEALTH INCORPORATED

      P/E-Ratio
      21.0
      Total Investment
      $19.6M
      Weight
      3.6%
      CORCEPT THERAPEUTICS INCORPORATED logo

      CORT - Manufacturing

      CORCEPT THERAPEUTICS INCORPORATED

      P/E-Ratio
      54.8
      Total Investment
      $19.2M
      Weight
      3.5%
      JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY logo

      JAZZ - Manufacturing

      JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

      P/E-Ratio
      -19.3
      Total Investment
      $18.1M
      Weight
      3.3%
      AXSOME THERAPEUTICS, INC. logo

      AXSM - Manufacturing

      AXSOME THERAPEUTICS, INC.

      P/E-Ratio
      -24.3
      Total Investment
      $11.9M
      Weight
      2.2%
      PRESTIGE CONSUMER HEALTHCARE INC. logo

      PRESTIGE CONSUMER HEALTHCARE INC.

      P/E-Ratio
      n/a
      Total Investment
      $10.9M
      Weight
      2.0%
      PERRIGO COMPANY PUBLIC LIMITED COMPANY logo

      PRGO - Manufacturing

      PERRIGO COMPANY PUBLIC LIMITED COMPANY

      P/E-Ratio
      -40.9
      Total Investment
      $10.2M
      Weight
      1.8%
      ORGANON & CO. logo

      OGN - Manufacturing

      ORGANON & CO.

      P/E-Ratio
      4.4
      Total Investment
      $6.96M
      Weight
      1.3%
      LIGAND PHARMACEUTICALS INCORPORATED logo

      LGND - Manufacturing

      LIGAND PHARMACEUTICALS INCORPORATED

      P/E-Ratio
      -41.1
      Total Investment
      $6.07M
      Weight
      1.1%
      SUPERNUS PHARMACEUTICALS, INC. logo

      SUPN - Manufacturing

      SUPERNUS PHARMACEUTICALS, INC.

      P/E-Ratio
      39.2
      Total Investment
      $4.88M
      Weight
      0.9%
      Tarsus Pharmaceuticals Inc logo

      TARS - Manufacturing

      Tarsus Pharmaceuticals Inc

      P/E-Ratio
      -8.5
      Total Investment
      $4.29M
      Weight
      0.8%
      AMNEAL PHARMACEUTICALS, INC. logo

      AMNEAL PHARMACEUTICALS, INC.

      P/E-Ratio
      n/a
      Total Investment
      $3.37M
      Weight
      0.6%
      HARMONY BIOSCIENCES HOLDINGS, INC. logo

      HARMONY BIOSCIENCES HOLDINGS, INC.

      P/E-Ratio
      n/a
      Total Investment
      $3.36M
      Weight
      0.6%
      OCULAR THERAPEUTIX, INC. logo

      OCUL - Manufacturing

      OCULAR THERAPEUTIX, INC.

      P/E-Ratio
      -9.7
      Total Investment
      $3.31M
      Weight
      0.6%
      ANI PHARMACEUTICALS, INC. logo

      ANIP - Manufacturing

      ANI PHARMACEUTICALS, INC.

      P/E-Ratio
      -168.1
      Total Investment
      $3.07M
      Weight
      0.6%
      INNOVIVA, INC. logo

      INVA - Manufacturing

      INNOVIVA, INC.

      P/E-Ratio
      33.2
      Total Investment
      $3.07M
      Weight
      0.6%
      PACIRA BIOSCIENCES, INC. logo

      PCRX - Manufacturing

      PACIRA BIOSCIENCES, INC.

      P/E-Ratio
      -9.5
      Total Investment
      $3.06M
      Weight
      0.6%
      HoMEÔçÒÒŮѸÀ×